

Commissioning guidance:

Commissioners may wish to bear the following in mind when considering the commissioning of eluxadoline:

- Current NICE guidance on the [management of irritable bowel syndrome \(IBS\) in adults \(CG61\)](#) advises loperamide as the first choice antimotility agent for diarrhoea in people with IBS followed by second-line options: tricyclic antidepressants (TCAs; at low dose [5 to 10 mg equivalent of amitriptyline, increase the dose if needed, but not usually beyond 30 mg]) or selective serotonin reuptake inhibitors (SSRIs) if TCAs are ineffective.
- It was the opinion of the committee that eluxadoline may be an alternative treatment option if treatment alternatives described in the NICE guidance have proved inappropriate or ineffective.

Strength of the evidence for efficacy

The evidence for eluxadoline was considered to be relatively weak. Two double-blind randomised controlled trials (RCTs) showed that eluxadoline-treated patients showed a greater response to a composite outcome of pain relief and stool consistency than with placebo but the European Medicines Agency commented that “this is considered of limited clinical relevance”, and “that response rates according to the EMA evaluation did not exceed 32%, meaning that indeed at least 2/3 of the treated population do not experience (full) response”.

MTRAC considered eluxadoline as a new product that may be used in primary care. This information is provided in advance of the product launch and may be subject to change.

References

1. [EU Draft Summary of Product Characteristics. EMA 2016](#)
2. [Irritable bowel syndrome. NICE CKS 2013](#)
3. [Assessment report: Truberzi. EMA 2016](#)
4. [Single Technology Appraisal: Eluxadoline for treating irritable bowel syndrome with diarrhoea \(Final scope\). NICE 2016](#)
5. [Clinical guideline CG61: Irritable bowel syndrome in adults - diagnosis and management. NICE 2008](#)
6. Lembo AJ et al. Eluxadoline for Irritable Bowel Syndrome with Diarrhea. *N Engl J Med* 2016; 374(3):242-253.
7. Guidelines on the irritable bowel syndrome: mechanisms and practical management. *Gut* 2007 http://www.bsg.org.uk/pdf_word_docs/ibs.pdf